Digest Network Come funziona
Network
/
Società
A2
Non verificato

A2 Biotherapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
03/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
A2 Biotherapeutics Presents Data from Ongoing Phase 1/2 EVEREST-2 Study During the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
26/06/2025
Oncologia
Salute
Biologia
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
09/01/2025
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
09/11/2024
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
04/10/2024
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
A2 Bio to Present Safety and Biomarker Data from EVEREST-1 Trial during 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0